Merck Message Board - Msg: 2871451

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck

MRK 111.01

+2.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Alan Wojtalik who wrote (432)	12/3/1997 9:21:00 PM
From: Bruce Russell	Read Replies (2) of 1580

Merck's answer to PROZAC. It this works better and has fewer side effects, then maybe Merck can fill the patent expiration whole after all! He revealed a promising new product candidate, MK-869, currently in phase II (early) clinical trials for the treatment of depression and other neuropsychiatric diseases. The once-a-day, oral compound has a novel mechanism of action, and in early trials demonstrated excellent antidepressant and anti-anxiety activity. In the trials it has shown excellent clinical tolerability and efficacy compared with a selective serotonin re-uptake inhibitor (SSRI) from the leading class of antidepressants.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next